NCT04123886View on ClinicalTrials.gov

A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion

PHASE1CompletedINTERVENTIONAL
Enrollment

14

Participants

Timeline

Start Date

January 8, 2020

Primary Completion Date

September 30, 2021

Study Completion Date

March 31, 2022

Conditions
Malignant Pleural Effusion
Interventions
DRUG

SCB-313

SCB-313 Intrapleural injection, once daily. Single dose on Day 1 in Cycle 0 followed by 7-day safety assessment, then dose on Day 1,2,3 in Cycle 1 followed by 21-day observation .

Trial Locations (1)

610000

West China Hospitial, Sichuan University, Chengdu

All Listed Sponsors
lead

Sichuan Clover Biopharmaceuticals, Inc.

INDUSTRY

NCT04123886 - A Phase I Study Evaluating SCB-313(Recombinant Human TRAIL-Trimer Fusion Protein) for the Treatment of Malignant Pleural Effusion | Biotech Hunter | Biotech Hunter